Literature DB >> 18778563

Inhibin and the regulation of bone mass.

Dana Gaddy1.   

Abstract

Inhibins A and B are gonadal peptide members of the transforming growth factor-beta superfamily that serve as negative feedback regulators of pituitary follicle-stimulating hormone (FSH). Accumulating evidence suggests that bone turnover and bone loss increase in women before menopause and the decrease in serum estradiol levels. Increased FSH levels have been correlated with some of these perimenopausal changes, whereas decreased inhibins strongly correlate with increases in bone formation and resorption across the menopause transition, and predict lumbar bone mass in perimenopausal women, likely resulting from the direct inhibin suppression of osteoblast and osteoclast development. Interestingly, continuous exposure of mice to inhibin A in vivo is anabolic and protective against gonadectomy-induced bone loss. Together, these data suggest inhibins contribute to the endocrine regulation of bone metabolism via a bimodal mechanism of action such that cycling inhibin exposure suppresses bone turnover, and continuous exposure to inhibins is anabolic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778563     DOI: 10.1007/s11914-008-0009-5

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  43 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

2.  FSH directly regulates bone mass.

Authors:  Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

3.  Ovarian aging and bone metabolism in menstruating women aged 35-50 years.

Authors:  Fisun Vural; Birol Vural; Izzet Yucesoy; Selim Badur
Journal:  Maturitas       Date:  2005-10-16       Impact factor: 4.342

4.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

5.  A prospective study of bone loss in menopausal Australian-born women.

Authors:  J R Guthrie; P R Ebeling; J L Hopper; E Barrett-Connor; L Dennerstein; E C Dudley; H G Burger; J D Wark
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

6.  Female reproductive aging is marked by decreased secretion of dimeric inhibin.

Authors:  C K Welt; D J McNicholl; A E Taylor; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

Review 7.  PTH: a future role in the management of osteoporosis?

Authors:  J Reeve
Journal:  J Bone Miner Res       Date:  1996-04       Impact factor: 6.741

8.  Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.

Authors:  Charles A O'Brien; Dan Jia; Lilian I Plotkin; Teresita Bellido; Cara C Powers; Scott A Stewart; Stavros C Manolagas; Robert S Weinstein
Journal:  Endocrinology       Date:  2003-12-22       Impact factor: 4.736

9.  A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men.

Authors:  B Lawrence Riggs; L Joseph Melton; Richard A Robb; Jon J Camp; Elizabeth J Atkinson; Lisa McDaniel; Shreyasee Amin; Peggy A Rouleau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2008-02       Impact factor: 6.741

10.  Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.

Authors:  Kellye C Kirkbride; Todd A Townsend; Monique W Bruinsma; Joey V Barnett; Gerard C Blobe
Journal:  J Biol Chem       Date:  2008-01-09       Impact factor: 5.157

View more
  6 in total

Review 1.  Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies.

Authors:  Sundeep Khosla
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Understanding estrogen action during menopause.

Authors:  Jameel Iqbal; Mone Zaidi
Journal:  Endocrinology       Date:  2009-08       Impact factor: 4.736

3.  Follicle-stimulating hormone increases bone mass in female mice.

Authors:  Charles M Allan; Robert Kalak; Colin R Dunstan; Kirsten J McTavish; Hong Zhou; David J Handelsman; Markus J Seibel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

4.  Signaling pathways implicated in androgen regulation of endocortical bone.

Authors:  Kristine M Wiren; Anthony A Semirale; Joel G Hashimoto; Xiao-Wei Zhang
Journal:  Bone       Date:  2009-11-04       Impact factor: 4.398

5.  Control of bone resorption by semaphorin 4D is dependent on ovarian function.

Authors:  Romain Dacquin; Chantal Domenget; Atsushi Kumanogoh; Hitoshi Kikutani; Pierre Jurdic; Irma Machuca-Gayet
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

6.  Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways.

Authors:  Francesco Elia Marino; Gail Risbridger; Elspeth Gold
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-05-23       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.